

June 9th, 2014

<News Release>

Pharmaceutical Research and Manufacturers of America (PhRMA)
European Federation of Pharmaceutical Industries and Associations (EFPIA)

**US and European Pharmaceutical Firms conducting 682 clinical trials
at 11,653 sites throughout Japan to develop innovative medicines
for Japanese patients**

PhRMA and EFPIA member companies spend 88 billion yen on clinical trials in Japan,
Saw approvals of 15 new drugs in 2013

PhRMA and EFPIA issued the joint report on the current situation of clinical research by foreign capital pharmaceutical companies in Japan, which titled "Research in Your Backyard" contains the data of researches for developing new drugs, which is available for each of the 47 prefectures and each of the 16 diseases supported by them.

The contributions made to Japan by foreign pharmaceutical companies as shown by this report are mainly as follows;

PhRMA and EFPIA member companies conduct 682 clinical trials in 11,653 sites yearly across all prefectures of Japan

PhRMA and EFPIA member companies carried out 682 clinical trials in 11,653 sites throughout the country in single year of 2013. These involved more than 16 therapeutic areas, including cancer, allergy, cardiology, gastroenterology, and rare diseases.


In the past 7 years, 132 new drugs from PhRMA and EFPIA companies were approved in Japan, including 15 drugs approved in 2013. To provide access to innovative drugs to patients in a timely manner, PhRMA and EFPIA members are increasing simultaneous global development including Japan to reduce the "drug lag."



The total clinical-related spending by PhRMA and EFPIA companies in Japan was 88 billion yen.

The total clinical-related spending by all pharmaceutical companies in Japan was 247 billion yen in 1,306 billion yen for all pharmaceutical R&D Spending in 2012.

Of this, PhRMA and EFPIA companies spending was 88 billion and this spending and investment is spread throughout the nation.



PhRMA and EFPIA think how these trials benefit Japan as follows;

First, medical facilities conducting clinical trials are able to provide advanced medical treatments to their patients, which mean to improve the quality of life for local patients. This is possible only because of physicians' participation in the trials.

Second, the spending on clinical trials in Japan goes to hospitals and clinics nationwide and supports the economy in every prefecture.

Third, these clinical trials create jobs throughout Japan as local medical facilities, pharmaceutical companies, SMO and CRO employ local staff to support clinical trials. And most of those jobs are high skilled, high paid, high value-added jobs.

These clinical trials represent the intellectual base of pharmaceutical industry. The value added of this industry is in the intellectual property they put into drug development. To sustain these investments, however, it is necessary to have supportive government policies in the areas of drug approval and pricing and reimbursement. PhRMA and EFPIA hope the related governmental offices in Japan will support these policies that are necessary to stimulate economic growth in Japan and provide the world's best medicines to Japanese patients.

*An iBook version of the report is also prepared for utilizing the data by iPad in where needed scenes, such as a presentation. Please see the whole report below, if you need.

<http://www.phrma-jp.org/>

- PhRMA Tokyo Office Website <http://www.phrma-jp.org>
- PhRMA Website <http://www.phrma.org>
- EFPIA JAPAN Website <http://efpia.jp/index.html>
- EFPIA Website <http://www.efpia.eu/>

For any media inquiries,
Contact Mitani, Aoki, Murata, Saiki at PhRMA PR Office (at Japan Counselors Inc.)
Tel: +81-3-3291-0118 Fax: 81-3-3291-0223
E-mail: phrma_pr@jc-inc.co.jp